uniQure N.V. QURE PHARMA

Q: What is the current share price of uniQure N.V. (QURE)?

As of 2026-09-19 21:16 PDT, uniQure N.V. (QURE) trades at $45.68 on NasdaqGS. Its 52-week range is $9.03 to $70.59.

Q: What is the market capitalisation of QURE?

uniQure N.V. (QURE) has a market capitalisation of $3.17B on NasdaqGS.

Q: What is the P/E ratio of QURE?

QURE trades at a trailing price-to-earnings (P/E) ratio of -11.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 9.41.

Q: Is QURE a good stock to buy?

This page provides a data-driven analysis of uniQure N.V. (QURE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · Netherlands

https://www.uniqure.com

Company Profile ↓

$45.68

+212.88% 1Y

Mkt Cap$3.17B

P/E-11.25

P/B9.41

52W High$70.59

52W Low$9.03

Book Value$4.67

EPS (TTM)$-4.06

Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Recent Developments

Dec 2025 Revenue of $16.10M (-40.6% YoY); net profit $-198.97M.
Trailing 12 Months Year-on-year growth — revenue +11.0%.
5-Year Trend Long-term compounding — revenue CAGR 9.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	9.16%
1 Year:	11.00%

Stock Price Performance

1 Year:	+212.88%
6 Months:	+153.92%
3 Months:	+69.19%
1 Month:	-1.59%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 60% of range

$9.03 $70.59

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)48.28 · Neutral

Price Performance

1M-1.59%

3M+69.19%

6M+153.92%

1Y+212.88%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading 35.3% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-11.25

Industry PE

24.83

Forward P/E

-15.17

PEG Ratio

Book Value

$4.67

Price to Book

9.41

P/S

163.46

EV/EBITDA

-15.28

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

9.16%

Profit 5Y

Revenue (YoY)

11.00%

Earnings (YoY)

Profitability & Returns

ROCE

-24.65%

ROE

ROA

-15.72%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$-1.22

EPS (TTM)

$-4.06

Balance Sheet & Liquidity

Debt/Equity

1.70

Quick Ratio

9.79

Current Ratio

10.01

Debt

$552.17M

Total Assets

$985.10M

Current Assets

$834.27M

Working Capital

$593.07M

Ownership

Promoter Holding

1.26%

Chg in Prom Hold

0.00%

FII / Inst Holding

98.04%

Chg in FII Hold

0.42%

Financial Snapshot

Enterprise Value

$3.17B

Total Revenue (TTM)

$18.67M

EBITDA

$-182.92M

Free Cash Flow

$-77.58M

Operating Cash Flow

$-160.79M

Shares Outstanding

69.37M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	QURE uniQure N.V. PHARMA	45.68	-11.25	$3.17B	0.00%	-24.65%	-	9.16%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.26M	3.70M	5.57M	3.56M	5.84M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	656.00K	398.00K	435.00K	219.00K	350.00K
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.61M	3.30M	5.13M	3.34M	5.49M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47.49M	52.79M	56.63M	47.61M	50.17M
Operating Income	-19.26M	-22.13M	-14.16M	-19.71M	-19.71M	-9.28M	-19.60M	-21.20M	-23.22M	-27.50M	-29.33M	-31.33M	-34.46M	-38.21M	-44.49M	-44.46M	398.01M	-45.00M	-54.08M	-56.06M	-59.52M	-74.17M	-65.07M	-81.88M	-54.23M	-44.01M	-40.23M	-	-42.88M	-49.49M	-51.49M	-44.27M	-44.68M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-18.07M	-51.55M	-23.46M	-36.06M	-59.95M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.59M	16.72M	14.57M	14.03M	14.37M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37.29M	-71.90M	-41.00M	-53.05M	-79.22M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	425.00K	8.63M	-3.92M	488.00K	1.84M
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56.30M	-44.38M	-	-37.72M	-80.53M	-37.09M	-53.53M	-81.06M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.96	-1.21	-0.91	8.51	-0.79	-1.00	-0.84	-1.02	-1.63	-1.44	-1.88	-1.36	-1.16	-0.91	-0.82	-0.69	-1.38	-	-0.85	-1.22
R&D Expense	16.71M	19.22M	16.60M	16.99M	16.87M	20.10M	17.06M	18.49M	20.54M	20.54M	24.15M	23.55M	26.01M	28.40M	36.30M	32.66M	32.75M	36.43M	45.00M	46.19M	48.07M	60.81M	46.04M	65.40M	40.69M	33.66M	30.59M	36.14M	35.38M	34.37M	-	29.18M	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	6.14M	10.58M	25.10M	13.11M	11.28M	7.28M	37.51M	524.00M	106.48M	15.84M	27.12M	16.10M
Cost of Revenue	-	-	-	-	-	-	-	-	3.34M	13.63M	18.33M	1.69M
Gross Profit	-	-	-	-	-	-	-	-	103.14M	2.21M	8.79M	14.41M
Operating Expenses	-	-	-	-	-	-	-	-	247.39M	284.70M	190.97M	202.24M
Operating Income	-53.68M	-71.15M	-71.95M	-71.34M	-88.23M	-121.14M	-125.43M	310.62M	-144.25M	-282.49M	-182.18M	-187.83M
EBITDA	-	-	-	-	-	-	-	-	-108.02M	-253.10M	-160.75M	-116.59M
Interest Expense	-	-	-	-	-	-	-	-	11.70M	41.56M	63.74M	61.99M
Pretax Income	-	-	-	-	-	-	-	-	-128.26M	-306.56M	-237.13M	-193.34M
Tax Provision	-	-	-	-	-	-	-	-	-1.47M	1.92M	2.43M	5.63M
Net Income	-49.78M	-82.08M	-73.37M	-79.26M	-83.30M	-124.20M	-125.02M	329.59M	-126.79M	-308.48M	-239.56M	-198.97M
Diluted EPS	-	-	-	-	-	-3.11	-2.81	7.04	-2.71	-6.47	-4.92	-3.46
R&D Expense	43.77M	59.12M	72.51M	72.17M	74.81M	94.74M	122.40M	143.55M	197.59M	214.86M	143.78M	140.67M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	262.66M	190.26M	209.64M	273.91M	448.63M	340.39M	-	704.96M	831.69M	556.54M	824.91M
Current Assets	-	-	-	-	-	-	-	-	-	476.77M	651.85M	390.29M	655.99M
Cash & Equivalents	32.78M	64.69M	221.63M	132.50M	159.37M	234.90M	377.79M	244.93M	-	228.01M	241.36M	158.93M	80.24M
Inventory	-	-	-	-	-	-	-	-	0	6.92M	12.02M	0	-
Receivables	-	-	-	-	-	-	-	-	-	102.38M	4.19M	5.88M	5.86M
Total Liabilities	-	-	134.74M	126.63M	120.28M	94.30M	125.57M	96.49M	-	228.96M	624.02M	563.29M	626.01M
Current Liabilities	-	-	26.91M	22.72M	19.23M	19.97M	31.63M	27.33M	-	75.92M	73.67M	40.05M	62.92M
Long Term Debt	-	-	14.63M	19.63M	19.74M	35.47M	36.06M	35.62M	-	102.79M	101.75M	51.32M	49.70M
Total Debt	-	-	-	-	-	-	-	-	-	142.89M	138.41M	66.06M	63.39M
Total Equity	2.29M	42.63M	127.93M	63.63M	89.36M	179.61M	323.06M	243.91M	-	476.01M	207.67M	-6.75M	198.90M
Shares Outstanding	-	-	-	-	-	-	-	-	-	46.97M	47.83M	48.99M	62.53M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	7.47M	-72.19M	-64.27M	-76.04M	-98.68M	-134.83M	-	-145.06M	-145.93M	-182.73M	-177.96M
Investing Cash Flow	-	-8.02M	-17.17M	-5.58M	-4.25M	-6.65M	-9.48M	-	-182.73M	-205.69M	162.97M	-321.62M
Financing Cash Flow	-	160.69M	2.44M	90.07M	157.96M	248.82M	7.44M	-	1.45M	362.72M	-59.49M	415.40M
Capital Expenditure	-22.20M	-7.61M	-15.29M	-4.46M	-2.38M	-5.65M	-7.27M	-	-17.69M	-7.15M	-11.69M	-439.00K
Free Cash Flow	-	-139.00K	-87.48M	-68.73M	-78.42M	-104.33M	-142.10M	-	-162.75M	-153.08M	-194.42M	-178.40M
Net Change in Cash	-	-	-	-	-	-	-	-	-326.35M	11.11M	-79.25M	-84.18M

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	96.9%	14.0%	32.4%	89.5%
Operating Margin %	-874.2%	-672.6%	-286.7%	-544.3%	-781.9%	-1,663.8%	-334.3%	59.3%	-135.5%	-1,783.0%	-671.8%	-1,166.8%
Net Margin %	-810.6%	-776.0%	-292.3%	-604.7%	-738.2%	-1,705.8%	-333.3%	62.9%	-119.1%	-1,947.1%	-883.4%	-1,236.0%
ROE %	-116.8%	-64.2%	-115.3%	-88.7%	-46.4%	-38.4%	-51.3%	-	-26.6%	-148.5%	3,547.9%	-100.0%
ROCE %	-	-30.2%	-42.9%	-37.5%	-34.7%	-29.1%	-40.1%	-	-22.9%	-37.3%	-35.3%	-24.6%

Shareholding Pattern

Insiders

1.26%

Institutions

98.04%

Public Float

99.29%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Avoro Capital Advisors LLC	9.70%	6.73M	$296.02M
2	JPMORGAN CHASE & CO	7.02%	4.87M	$214.18M
3	RTW Investments LP	5.68%	3.94M	$173.43M
4	State Street Corporation	4.19%	2.90M	$127.77M
5	Aberdeen Group plc	4.11%	2.85M	$125.32M
6	Blackrock Inc.	2.71%	1.88M	$82.61M
7	Orbimed Advisors LLC.	2.61%	1.81M	$79.53M
8	Jane Street Group, LLC	2.32%	1.61M	$70.86M
9	Jennison Associates LLC	2.25%	1.56M	$68.70M
10	Boxer Capital Management, LLC	2.17%	1.50M	$66.15M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for QURE

Google News hu, 03 Sep 2026

uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNZHkxdUs0eUZTclB4eU1JX0pqeU9PZ1VNYW5Xampycl9NeFlVX0JnajJrMl91SVdfb0xLV3dpNkI4VG9TVXZhU21GZEliSHR6NGw4NUZCOEVBcDJMWHhJRm1abDNFSXNRTElYSGp1TzNjaUtLZXNYWHowZ29hZ1B6ME5fanpIOHMyc3BHUV…

Google News ue, 08 Sep 2026

uniQure (QURE) Could Be 36% Undervalued Following Its AMT 130 FDA Filing - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPVlJuYWJ3U1lPWThFYmt4dW1zeE1xN0VEZ3VCb3ZEY2xCLUhkTFBBVnlRWF9fZEo2cHFjSnN4bHJiVG5UT2FmMzVwaXhrMElHdGoxVlp4ZElLOXphWjJSaEJLSDYxOFBjY0MxaUJwVGpTQlo4Sks5TzlIZ3lkUFREQkp6bmxyVFhoQVVlVU…

Google News Mon, 07 Sep 2026

QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbmd2bkJFdUFsRC1PSzc5eDRRNWR0UG1LbzVHVnh1Tk4zd3BlTktwSlEycGNJa0F4T1YyNlhhRjN0M2xPam51NTBPdzhXOXJtdjVhb1B1YXBuemVTQjdFejBnYUg1dTlXSEx5Rm8zdkdZUVpyaHJnME1qalJUREFzOFdiS0lnVGpVQWlaSz…

Google News Wed, 02 Sep 2026

QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside - TradingView

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNN0lqSG1qazYxN0ZNS1JhUDVId25KaFNPOVBJNFdJOGIwaDBvRVVBcm9GemNfWXpwNkFRLTdreU5VME1acVlvNGVfV3BNSk1xdnY1dzhkUVJMVWhjdnNBbng1NFE0dDVzbDVJam5xN3E5eGRGLTF3QVM0ckdsTlZKeVI5dkhVdG16RnRPTk…

Google News Sun, 06 Sep 2026

Uniqure (QURE) Total Assets 2025: $824.9M, up 48.2% - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE0tUzY1aGlxZjY1ZFV0RVFhc1lrckljRFBIbzB2OU9KN2RlTmdIMXJTS01IVjFSbDg2ekc1LTNlQm1veUwtQWJaY3g2bWc3cVBJSkh4REY3dXJTYXpxdGdNWnpMc3BBUGE4?oc=5" target="_blank">Uniqure (QURE) Total Assets…

Google News Sat, 05 Sep 2026

Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxORDFGSGF0MUhrZXQyckxJZ291VVZxU3V3VWRIcG14cFV3TjRocnp6aGhUQVdEYm1RdnE0SjZfNmRqUmx4Z200U05NWXJvNmtSUXpHSWQwbVJXQVJVNFYxdV9IN2Y2aHprZ3NzM2FlZHlrM1dJbzVtMHlrVmFoTzRiSzVlbS1mMkg4TzBBNF…

QURE — Frequently Asked Questions

What is the current share price of uniQure N.V. (QURE)?

As of 2026-09-19 21:16 PDT, uniQure N.V. (QURE) trades at $45.68 on NasdaqGS. Its 52-week range is $9.03 to $70.59.

What is the market capitalisation of QURE?

uniQure N.V. (QURE) has a market capitalisation of $3.17B on NasdaqGS.

What is the P/E ratio of QURE?

QURE trades at a trailing price-to-earnings (P/E) ratio of -11.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 9.41.

Is QURE a good stock to buy?

This page provides a data-driven analysis of uniQure N.V. (QURE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

uniQure N.V. QURE PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - finance.yahoo.com

uniQure (QURE) Could Be 36% Undervalued Following Its AMT 130 FDA Filing - simplywall.st

QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits

QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside - TradingView

Uniqure (QURE) Total Assets 2025: $824.9M, up 48.2% - Stock Titan

Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily

QURE — Frequently Asked Questions

What is the current share price of uniQure N.V. (QURE)?

What is the market capitalisation of QURE?

What is the P/E ratio of QURE?

Is QURE a good stock to buy?

Explore More